X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Divis Laboratories with Aurobindo Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DIVIS LABORATORIES vs AUROBINDO PHARMA - Comparison Results

DIVIS LABORATORIES    Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

AUROBINDO PHARMA 
   Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DIVIS LABORATORIES AUROBINDO PHARMA DIVIS LABORATORIES/
AUROBINDO PHARMA
 
P/E (TTM) x 29.0 14.0 207.6% View Chart
P/BV x 5.0 3.6 140.0% View Chart
Dividend Yield % 1.0 0.4 226.7%  

Financials

 DIVIS LABORATORIES   AUROBINDO PHARMA
EQUITY SHARE DATA
    DIVIS LABORATORIES
Mar-17
AUROBINDO PHARMA
Mar-17
DIVIS LABORATORIES/
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs1,222895 136.5%   
Low Rs784622 126.0%   
Sales per share (Unadj.) Rs153.1254.6 60.1%  
Earnings per share (Unadj.) Rs39.939.3 101.7%  
Cash flow per share (Unadj.) Rs44.646.6 95.7%  
Dividends per share (Unadj.) Rs10.002.50 400.0%  
Dividend yield (eoy) %1.00.3 302.5%  
Book value per share (Unadj.) Rs201.8160.0 126.2%  
Shares outstanding (eoy) m265.47585.88 45.3%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x6.63.0 219.9%   
Avg P/E ratio x25.119.3 130.0%  
P/CF ratio (eoy) x22.516.3 138.1%  
Price / Book Value ratio x5.04.7 104.8%  
Dividend payout %25.06.4 393.3%   
Avg Mkt Cap Rs m266,266444,390 59.9%   
No. of employees `0009.714.0 69.6%   
Total wages/salary Rs m4,68717,678 26.5%   
Avg. sales/employee Rs Th4,175.010,667.8 39.1%   
Avg. wages/employee Rs Th481.51,264.3 38.1%   
Avg. net profit/employee Rs Th1,089.31,645.8 66.2%   
INCOME DATA
Net Sales Rs m40,643149,157 27.2%  
Other income Rs m7491,159 64.6%   
Total revenues Rs m41,392150,316 27.5%   
Gross profit Rs m14,46034,343 42.1%  
Depreciation Rs m1,2334,276 28.8%   
Interest Rs m23667 3.4%   
Profit before tax Rs m13,95330,558 45.7%   
Minority Interest Rs m050 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3,3497,597 44.1%   
Profit after tax Rs m10,60423,012 46.1%  
Gross profit margin %35.623.0 154.5%  
Effective tax rate %24.024.9 96.6%   
Net profit margin %26.115.4 169.1%  
BALANCE SHEET DATA
Current assets Rs m40,10592,062 43.6%   
Current liabilities Rs m6,59566,223 10.0%   
Net working cap to sales %82.517.3 476.0%  
Current ratio x6.11.4 437.5%  
Inventory Days Days119106 111.9%  
Debtors Days Days8168 119.2%  
Net fixed assets Rs m19,99562,919 31.8%   
Share capital Rs m531586 90.6%   
"Free" reserves Rs m53,04393,133 57.0%   
Net worth Rs m53,57493,719 57.2%   
Long term debt Rs m01,814 0.0%   
Total assets Rs m61,585162,494 37.9%  
Interest coverage x618.446.8 1,321.4%   
Debt to equity ratio x00 0.0%  
Sales to assets ratio x0.70.9 71.9%   
Return on assets %17.314.6 118.4%  
Return on equity %19.824.6 80.6%  
Return on capital %26.132.7 79.7%  
Exports to sales %00-   
Imports to sales %25.20-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs m10,259NA-   
Fx inflow Rs m35,38475,838 46.7%   
Fx outflow Rs m10,39930,224 34.4%   
Net fx Rs m24,98545,613 54.8%   
CASH FLOW
From Operations Rs m11,49332,786 35.1%  
From Investments Rs m-11,372-17,870 63.6%  
From Financial Activity Rs m-93-19,153 0.5%  
Net Cashflow Rs m28-4,239 -0.7%  

Share Holding

Indian Promoters % 52.0 54.1 96.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.8 8.0 148.4%  
FIIs % 19.0 27.7 68.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.2 10.2 168.6%  
Shareholders   31,796 69,601 45.7%  
Pledged promoter(s) holding % 0.0 8.6 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DIVIS LABORATORIES With:   STERLING BIOTECH  PFIZER  ALKEM LABORATORIES  ORCHID PHARMA LTD  SANOFI INDIA  

Compare DIVIS LABORATORIES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes Marginally Lower; Capital Goods & Realty Stocks Fall(Closing)

Indian share markets witnessed selling pressure in the final hour of trade to finish just below the dotted line. At the closing bell, the BSE Sensex closed lower by 71 points.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Follow India's Super Investors to Make Big Money in the Market Crash(The 5 Minute Wrapup)

Feb 8, 2018

Has the sell-off in the markets left India's super investors unduly worried?

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

Rising Dominance of Mutual Funds(Chart Of The Day)

Feb 8, 2018

Domestic money flow into Indian equities surpassed foreign fund flows in the recent years. But will it continue in volatile market?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DIVIS LABORATORIES SHARE PRICE


Feb 20, 2018 (Close)

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES 5-YR ANALYSIS

COMPARE DIVIS LABORATORIES WITH

MARKET STATS